Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC

The anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) have been administered to patients with ALK-positive non-small cell lung cancer for a long period of time and show a promising response. However, the differences in the toxicity profiles among these drugs are still unclear. | Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN
TÀI LIỆU MỚI ĐĂNG
152    3    1    09-05-2021